Immunocore Holdings is a commercial-stage T cell receptor biotechnology company working to develop and commercialize transformative medicines for oncology, infectious diseases and autoimmune and inflammation diseases. In a confirmed uptrend, yesterday signaled a good pivot buy where I placed an initial position. I liked the volatility contraction pattern and...
$ABCL a favorite long term but risk ahead if markets falter as revenue from Covid treatment stops coming in
Currently trading mid 4's with a market cap under 100 million it's way to cheap for the Robust pipeline including the recent addition from Taurus adensonine pipeline Structure Shs Outstand 16.74M Shs Float 10.13M Expect Catalyst Data readouts from pipeline Research Pipeline Merck, lead asset Port-2 (inkt)/trial designed with Merck Technical Bottom
Trade levels are: Entry price: $12.53 Take profit: $14.04 Stop loss: $11.96 Risk/reward: 2,65
On the weekly chart, price seemed to be breaking down from a channel and then reversed course to move higher. If this is a rubberband reaction and risk-off resumes, then this monthly frame shows a 2nd leg down that could move to 62-58. Alternatively, if risk-on stays the course to continue January's rise, then price moves up to the 20ma, 96-100 area. Watch daily...
Price diverging from the 11EMA and 60 VMA. Breakdown should send this to 5.10 and ATL. That might be last impulse move to downside. 4.5 would another zone of interest for bottom. no reason to be bullish here. Downside capitulation risk is high here.
Biotech in my opinion will be the biggest sector of growth in the 21st Century. Lot of value here in this ETF and it has the potential to explode in growth for a long time. Other good ETFs for this sector are ARKG IBB XBI. New highs in the next few years is my call on GNOM
I've become interested in BZYR which trades only OTC at this time. Why is this OTC stock of high importance for long term investors? In order to set this out my post is broken into various parts: 1 - Introduction 2 - The historical battles 3 - Efficacy of a cancer treatment 4 - Summary 5 - The risk to reward for long term investors. The above cannot possibly...
Clean bottoming pattern formed as well as clean shifting of momentum here Look for the bull flag breakout of the head and shoulders for 10-15% upside here
This analysis is for educational purposes only and is not a recommendation to buy or sell
- I like the powerful move it is sustaining - Volume signature is looking great - Strong industry group
Crazy volume on this one relative to it's history and .58 supply test and rejection but stock is still hovering above .4 resistance which is promising for longs. I'm in at .3 and holding for .7 Target, to trim some along the way.
Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin...
Holding 23.6 fib level, looking for a potential retest of 38.6 fib level at 1.46 and find support and confirm trend reversal back towards HOD.
Biotechnology is the favorite sector of one of our analysts, most of his portfolio consists of biotechs, and he himself claims that it is the cryptocurrency of the common stock market. Why? Let's explain : High risk/reward and high volatility. Imagine this: you invest in a company that has no revenue or any specific product, yet you believe in the idea it...
if we continue this bear reversal in biotech labd may cross signal and estimate bull and reach for upper envelope in a reverse head and shouldern pattern. if we carve a path higher in major indices i expect biotech to follow.
Hi again, I see that you are back near buy point. I'll buy if the price breaks above this range at $31.50 and add more once breaks to a new all time high at $34. The stock highly volatile, so I suggest starting with small positions and/or staggered stops.
Oversold likely due related to tax loss selling. Solid Q3 financials. Large insider buys. $10 price target from Scotiabank analyst.